Search

Additional file 1: Appendix Information 1. Methodology of the included studies. Appendix information 2. Ethical clearance obtained. Appendix Table 1. Epilepsy screening questionnaire Malawi. Appendix Table 2. Epilepsy screening questionnaire Uganda. Appendix Table 3. Type and dosage of ASM among patients treated with monotherapy¥.

Additional file 1. Reporting checklist for protocol of a clinical trial based on the SPIRIT guidelines.

Additional file 1: Figure S1. The results of the questionnaire regarding hearing and understanding in absolute numbers (n = 31). Figure S2. The wave reproducibility rates of each ear (left and right) are compared according to the setting in which the measurement was taken: at the research facility (CERMEL, Centre des Rechèrches Médicales Lambaréné, n = 15) or at home (n = 16). Statistical significance is assessed using independent samples t-test. Table S1. Of the 31 patients that could be included in the follow-up study, 15 were assessed in the research facility and 16 at home.

Country sheets template. (DOCX 47 kb)

Identified taeniosis cases in case reports in western Europe (1990–2015). Table S5. Aggregated taeniosis cases reported in authorities’ reports, epidemiological bulletins, and national registries in western Europe (1990–2015). Table S6. Aggregated taeniosis cases reported at hospital/laboratory level in western Europe (1990–2015). Table S7. Taeniosis prevalence data reported in epidemiological studies (1990–2015). Table S8. Taeniosis estimates published in western Europe (1990–2015). Table S9. Identified human cysticercosis cases in case reports in western Europe (1990–2015). Table S10. Aggregated human cysticercosis cases identified in registries and reports in western Europe (1990–2015). Table S11. Aggregated human cysticercosis cases reported at hospital/laboratory level in western Europe (1990–2015). Table S12. Porcine cysticercosis cases and prevalence reported in western Europe (1990–2015) based on meat inspection. Table S13. Bovine cysticercosis cases reported (when prevalence not available) in western Europe (1990–2015) based on meat inspection. Table S14. Bovine cysticercosis prevalence detected in western Europe (1990–2015) by more sensitive methods than routine meat inspection. Table S15. Bovine cysticercosis prevalence data per age reported in western Europe (1990–2015) based on routine meat inspection. (DOCX 99 kb)

PRISMA 2009 Checklist. (DOC 64 kb)

Identified taeniosis cases in case reports in western Europe (1990–2015). Table S5. Aggregated taeniosis cases reported in authorities’ reports, epidemiological bulletins, and national registries in western Europe (1990–2015). Table S6. Aggregated taeniosis cases reported at hospital/laboratory level in western Europe (1990–2015). Table S7. Taeniosis prevalence data reported in epidemiological studies (1990–2015). Table S8. Taeniosis estimates published in western Europe (1990–2015). Table S9. Identified human cysticercosis cases in case reports in western Europe (1990–2015). Table S10. Aggregated human cysticercosis cases identified in registries and reports in western Europe (1990–2015). Table S11. Aggregated human cysticercosis cases reported at hospital/laboratory level in western Europe (1990–2015). Table S12. Porcine cysticercosis cases and prevalence reported in western Europe (1990–2015) based on meat inspection. Table S13. Bovine cysticercosis cases reported (when prevalence not available) in western Europe (1990–2015) based on meat inspection. Table S14. Bovine cysticercosis prevalence detected in western Europe (1990–2015) by more sensitive methods than routine meat inspection. Table S15. Bovine cysticercosis prevalence data per age reported in western Europe (1990–2015) based on routine meat inspection. (DOCX 99 kb)

Supplementary material. (DOC 123 kb)